JP2020526575A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2020526575A5 JP2020526575A5 JP2020519196A JP2020519196A JP2020526575A5 JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5 JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020519196 A JP2020519196 A JP 2020519196A JP 2020526575 A5 JP2020526575 A5 JP 2020526575A5
- Authority
- JP
- Japan
- Prior art keywords
- migraine
- leucine
- pharmaceutical composition
- acceptable salt
- composition according
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000003839 salts Chemical class 0.000 claims description 133
- 229960000669 acetylleucine Drugs 0.000 claims description 69
- WXNXCEHXYPACJF-ZETCQYMHSA-N N-acetyl-L-leucine Chemical compound CC(C)C[C@@H](C(O)=O)NC(C)=O WXNXCEHXYPACJF-ZETCQYMHSA-N 0.000 claims description 68
- 206010027599 migraine Diseases 0.000 claims description 49
- 208000019695 Migraine disease Diseases 0.000 claims description 47
- 230000002265 prevention Effects 0.000 claims description 37
- 208000024891 symptom Diseases 0.000 claims description 19
- 239000002243 precursor Substances 0.000 claims description 13
- KRQUFUKTQHISJB-YYADALCUSA-N 2-[(E)-N-[2-(4-chlorophenoxy)propoxy]-C-propylcarbonimidoyl]-3-hydroxy-5-(thian-3-yl)cyclohex-2-en-1-one Chemical compound CCC\C(=N/OCC(C)OC1=CC=C(Cl)C=C1)C1=C(O)CC(CC1=O)C1CCCSC1 KRQUFUKTQHISJB-YYADALCUSA-N 0.000 claims description 10
- 206010019233 Headaches Diseases 0.000 claims description 10
- 231100000869 headache Toxicity 0.000 claims description 10
- 208000002173 dizziness Diseases 0.000 claims description 8
- 206010020751 Hypersensitivity Diseases 0.000 claims description 6
- 206010028813 Nausea Diseases 0.000 claims description 6
- 208000026935 allergic disease Diseases 0.000 claims description 6
- 230000009610 hypersensitivity Effects 0.000 claims description 6
- 230000008693 nausea Effects 0.000 claims description 6
- 230000001720 vestibular Effects 0.000 claims description 5
- 206010003791 Aura Diseases 0.000 claims description 4
- 206010015037 epilepsy Diseases 0.000 claims description 4
- IVWWFWFVSWOTLP-YVZVNANGSA-N (3'as,4r,7'as)-2,2,2',2'-tetramethylspiro[1,3-dioxolane-4,6'-4,7a-dihydro-3ah-[1,3]dioxolo[4,5-c]pyran]-7'-one Chemical compound C([C@@H]1OC(O[C@@H]1C1=O)(C)C)O[C@]21COC(C)(C)O2 IVWWFWFVSWOTLP-YVZVNANGSA-N 0.000 claims description 3
- 208000004998 Abdominal Pain Diseases 0.000 claims description 3
- 208000012639 Balance disease Diseases 0.000 claims description 3
- 206010012735 Diarrhoea Diseases 0.000 claims description 3
- 208000004044 Hypesthesia Diseases 0.000 claims description 3
- 208000016285 Movement disease Diseases 0.000 claims description 3
- 208000002193 Pain Diseases 0.000 claims description 3
- 206010034972 Photosensitivity reaction Diseases 0.000 claims description 3
- 208000003443 Unconsciousness Diseases 0.000 claims description 3
- 206010047571 Visual impairment Diseases 0.000 claims description 3
- 208000034783 hypoesthesia Diseases 0.000 claims description 3
- 231100000862 numbness Toxicity 0.000 claims description 3
- 208000035824 paresthesia Diseases 0.000 claims description 3
- 230000036211 photosensitivity Effects 0.000 claims description 3
- 230000035900 sweating Effects 0.000 claims description 3
- 208000029257 vision disease Diseases 0.000 claims description 3
- 230000000007 visual effect Effects 0.000 claims description 3
- 230000004393 visual impairment Effects 0.000 claims description 3
- 206010050258 Basilar migraine Diseases 0.000 claims description 2
- 208000010541 Familial or sporadic hemiplegic migraine Diseases 0.000 claims description 2
- 206010019476 Hemiplegic migraine Diseases 0.000 claims description 2
- 208000000060 Migraine with aura Diseases 0.000 claims description 2
- 206010052784 Retinal migraine Diseases 0.000 claims description 2
- 206010016256 fatigue Diseases 0.000 claims description 2
- 208000017420 migraine with brainstem aura Diseases 0.000 claims description 2
- 239000008194 pharmaceutical composition Substances 0.000 claims 21
- 206010016326 Feeling cold Diseases 0.000 claims 1
- 208000035238 familial hemiplegic 1 migraine Diseases 0.000 claims 1
- 230000003252 repetitive effect Effects 0.000 claims 1
- 208000006122 sporadic hemiplegic migraine Diseases 0.000 claims 1
- ROHFNLRQFUQHCH-YFKPBYRVSA-N L-leucine Chemical compound CC(C)C[C@H](N)C(O)=O ROHFNLRQFUQHCH-YFKPBYRVSA-N 0.000 description 65
- ROHFNLRQFUQHCH-UHFFFAOYSA-N Leucine Natural products CC(C)CC(N)C(O)=O ROHFNLRQFUQHCH-UHFFFAOYSA-N 0.000 description 65
- 239000003814 drug Substances 0.000 description 14
- 229940079593 drug Drugs 0.000 description 10
- 238000000034 method Methods 0.000 description 7
- 230000035807 sensation Effects 0.000 description 4
- 208000037048 Prodromal Symptoms Diseases 0.000 description 2
- 230000001154 acute effect Effects 0.000 description 2
- 210000003169 central nervous system Anatomy 0.000 description 2
- 238000007913 intrathecal administration Methods 0.000 description 2
- 230000000306 recurrent effect Effects 0.000 description 2
- 206010027603 Migraine headaches Diseases 0.000 description 1
- 238000007917 intracranial administration Methods 0.000 description 1
- 238000007914 intraventricular administration Methods 0.000 description 1
- 230000003902 lesion Effects 0.000 description 1
- 230000002093 peripheral effect Effects 0.000 description 1
- 230000001225 therapeutic effect Effects 0.000 description 1
- 238000002054 transplantation Methods 0.000 description 1
Applications Claiming Priority (2)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| GBGB1709459.0A GB201709459D0 (en) | 2017-06-14 | 2017-06-14 | Treatment for migraine |
| PCT/IB2018/054676 WO2018229738A1 (en) | 2017-06-14 | 2018-06-25 | Treatment for migraine |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2020526575A JP2020526575A (ja) | 2020-08-31 |
| JP2020526575A5 true JP2020526575A5 (enExample) | 2021-08-12 |
| JP7130739B2 JP7130739B2 (ja) | 2022-09-05 |
Family
ID=59358204
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2020519196A Active JP7130739B2 (ja) | 2017-06-14 | 2018-06-25 | 片頭痛の治療 |
Country Status (25)
| Country | Link |
|---|---|
| US (1) | US11471434B2 (enExample) |
| EP (1) | EP3638370B1 (enExample) |
| JP (1) | JP7130739B2 (enExample) |
| KR (1) | KR102594130B1 (enExample) |
| CN (1) | CN111093772B (enExample) |
| AU (1) | AU2018284330B2 (enExample) |
| CY (1) | CY1123860T1 (enExample) |
| DK (1) | DK3638370T3 (enExample) |
| ES (1) | ES2847169T3 (enExample) |
| GB (1) | GB201709459D0 (enExample) |
| HR (1) | HRP20210108T1 (enExample) |
| HU (1) | HUE053089T2 (enExample) |
| IL (1) | IL271211B2 (enExample) |
| LT (1) | LT3638370T (enExample) |
| MA (1) | MA49396B1 (enExample) |
| MD (1) | MD3638370T2 (enExample) |
| MX (1) | MX387909B (enExample) |
| PL (1) | PL3638370T3 (enExample) |
| PT (1) | PT3638370T (enExample) |
| RS (1) | RS61481B1 (enExample) |
| SG (1) | SG11201912146RA (enExample) |
| SI (1) | SI3638370T1 (enExample) |
| SM (1) | SMT202100037T1 (enExample) |
| WO (1) | WO2018229738A1 (enExample) |
| ZA (1) | ZA201908087B (enExample) |
Families Citing this family (2)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| CA3091353A1 (en) * | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| BR112021010923A2 (pt) | 2018-12-06 | 2021-08-24 | Intrabio Ltd | Análogos deuterados de acetileucina |
Family Cites Families (26)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| SE8701662L (sv) * | 1987-04-22 | 1988-10-23 | Gelder Nico M Van | Saett och medel foer att behandla neurologiska sjukdomar, exempelvis migraen genom paaverkan av nervcellerna |
| US20040127501A1 (en) * | 2002-09-24 | 2004-07-01 | Zhengming Chen | Therapeutic agents useful for treating pain |
| US20060063827A1 (en) | 2004-09-23 | 2006-03-23 | Yu Ruey J | Systemic administration of therapeutic amino acids and N-acetylamino acids |
| MY142655A (en) * | 2003-06-12 | 2010-12-15 | Euro Celtique Sa | Therapeutic agents useful for treating pain |
| SI1641775T1 (sl) * | 2003-07-03 | 2009-08-31 | Euro Celtique Sa | 2-piridin alkinski derivati, uporabni za zdravljenje bolečine |
| EP2080757A1 (en) * | 2003-07-24 | 2009-07-22 | Euro-Celtique S.A. | Heteroaryl-tetrahydropiperidyl compounds useful for treating or preventing pain |
| DE602004017481D1 (de) * | 2003-09-22 | 2008-12-11 | Euro Celtique Sa | Zur behandlung von schmerzen geeignete therapeutische mittel |
| PT2017276E (pt) * | 2003-09-22 | 2011-04-05 | Euro Celtique Sa | Compostos de fenilcarboxamida úteis para o tratamento da dor |
| CN1902178A (zh) * | 2003-12-30 | 2007-01-24 | 欧洲凯尔特公司 | 用于治疗疼痛的哌嗪 |
| FR2905600B1 (fr) * | 2006-09-13 | 2010-01-15 | Pf Medicament | Traitement des vertiges par l'acetyl-l-leucine. |
| TN2010000251A1 (fr) | 2010-06-03 | 2011-11-11 | Rekik Raouf | N-acetyl-dl-leucine medicament neuro et retino protecteur |
| JP5876423B2 (ja) * | 2010-06-22 | 2016-03-02 | 塩野義製薬株式会社 | Ｔｒｐｖ１阻害活性を有する化合物とその使用 |
| EP2588130B1 (en) | 2010-06-25 | 2016-08-17 | Shire Human Genetic Therapies, Inc. | Cns delivery of therapeutic agents |
| EP3536368B1 (en) * | 2010-11-09 | 2025-09-17 | MannKind Corporation | Dry powder inhaler comprising a serotonin receptor agonist and a diketopiperazine for treating migraines |
| AU2012293417A1 (en) * | 2011-08-10 | 2013-05-02 | Purdue Pharma L.P. | TRPV1 antagonists including dihydroxy substituent and uses thereof |
| WO2017182802A1 (en) | 2016-04-19 | 2017-10-26 | Intrabio Ltd | Acetyl-leucine or a pharmaceutically acceptable salt thereof for improved mobility and cognitive function |
| KR102467953B1 (ko) | 2016-08-11 | 2022-11-16 | 인트라바이오 리미티드 | 리소좀 축적 질환과 관련된 약제 조성물 및 용도 |
| MA43828B1 (fr) | 2016-08-11 | 2019-09-30 | Intrabio Ltd | Agents thérapeutiques pour maladies neurodégénératives |
| WO2018178670A1 (en) | 2017-03-28 | 2018-10-04 | Intrabio Ltd | Betahistine, or a pharmaceutically acceptable salt thereof, and a monoamine oxidase inhibitor, for use in the treatment or prevention of one or more symptoms of vertigo in a subject |
| MA50399A (fr) | 2017-10-18 | 2020-08-26 | Intrabio Ltd | Agents thérapeutiques pour mobilité et fonction cognitive améliorées et pour le traitement de maladies neurodégénératives et de troubles de stockage lysosomal |
| SG11202003390UA (en) | 2017-10-18 | 2020-05-28 | Intrabio Ltd | Therapeutic agents for neurodegenerative diseases |
| CA3091353A1 (en) | 2018-02-15 | 2019-08-22 | Intrabio Ltd | Therapeutic agents for treating restless legs syndrome |
| BR112021010923A2 (pt) | 2018-12-06 | 2021-08-24 | Intrabio Ltd | Análogos deuterados de acetileucina |
| KR20250171484A (ko) | 2019-03-02 | 2025-12-08 | 인트라바이오 리미티드 | 질환을 치료하기 위한 류신, 아세틸 류신, 및 관련된 유사체 |
| US20220362189A1 (en) | 2019-06-28 | 2022-11-17 | Intrabio Ltd. | Combination therapy with acetyl-leucine and miglustat |
| WO2021144720A1 (en) | 2020-01-13 | 2021-07-22 | Intrabio Ltd | Treatment of late-onset neurodegenerative diseases in heterozygous npc1 gene mutation carriers |
-
2017
- 2017-06-14 GB GBGB1709459.0A patent/GB201709459D0/en not_active Ceased
-
2018
- 2018-06-25 AU AU2018284330A patent/AU2018284330B2/en active Active
- 2018-06-25 LT LTEP18749124.6T patent/LT3638370T/lt unknown
- 2018-06-25 SI SI201830195T patent/SI3638370T1/sl unknown
- 2018-06-25 EP EP18749124.6A patent/EP3638370B1/en active Active
- 2018-06-25 PT PT187491246T patent/PT3638370T/pt unknown
- 2018-06-25 PL PL18749124T patent/PL3638370T3/pl unknown
- 2018-06-25 SG SG11201912146RA patent/SG11201912146RA/en unknown
- 2018-06-25 MX MX2019014784A patent/MX387909B/es unknown
- 2018-06-25 RS RS20210046A patent/RS61481B1/sr unknown
- 2018-06-25 HU HUE18749124A patent/HUE053089T2/hu unknown
- 2018-06-25 WO PCT/IB2018/054676 patent/WO2018229738A1/en not_active Ceased
- 2018-06-25 IL IL271211A patent/IL271211B2/en unknown
- 2018-06-25 HR HRP20210108TT patent/HRP20210108T1/hr unknown
- 2018-06-25 MD MDE20200433T patent/MD3638370T2/ro unknown
- 2018-06-25 ES ES18749124T patent/ES2847169T3/es active Active
- 2018-06-25 KR KR1020197038730A patent/KR102594130B1/ko active Active
- 2018-06-25 US US16/622,785 patent/US11471434B2/en active Active
- 2018-06-25 CN CN201880039532.2A patent/CN111093772B/zh active Active
- 2018-06-25 MA MA49396A patent/MA49396B1/fr unknown
- 2018-06-25 DK DK18749124.6T patent/DK3638370T3/da active
- 2018-06-25 JP JP2020519196A patent/JP7130739B2/ja active Active
- 2018-06-25 SM SM20210037T patent/SMT202100037T1/it unknown
-
2019
- 2019-12-05 ZA ZA2019/08087A patent/ZA201908087B/en unknown
-
2021
- 2021-01-18 CY CY20211100033T patent/CY1123860T1/el unknown
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2022153638A5 (enExample) | ||
| JP2026035701A5 (enExample) | ||
| JP2023181322A (ja) | 睡眠時無呼吸を治療するための方法および組成物 | |
| IL315023A (en) | Neuroactive steroids for treatment of cns-related disorders | |
| JP2020516646A5 (enExample) | ||
| JP2023500032A5 (enExample) | ||
| JPWO2019065900A1 (ja) | 神経変性疾患あるいは認知機能障害の予防または治療剤としてのｒ−ケタミンおよびその誘導体 | |
| JP2023552700A5 (enExample) | ||
| JP2023073373A5 (enExample) | ||
| JP2007182440A (ja) | アゴメラチンの、口腔粘膜または舌下投与のための口内分散性医薬組成物 | |
| JP2021530543A5 (enExample) | ||
| JP2025508004A5 (enExample) | ||
| JP2016505050A5 (enExample) | ||
| AU1774192A (en) | Composition and method containing optically pure (s) metoprolol | |
| CN101610760A (zh) | 恶病质的治疗 | |
| JP2025508051A5 (enExample) | ||
| Moore et al. | Management of Motor | |
| JP2024527175A5 (enExample) | ||
| Sweet et al. | Methyldopa as an adjunct to levodopa treatment of Parkinson's disease | |
| JP2023537369A5 (enExample) | ||
| JP2021530568A5 (enExample) | ||
| JP2022504435A5 (enExample) | ||
| JP2015515971A5 (enExample) | ||
| JP2020526575A (ja) | 片頭痛の治療 | |
| JP2025505578A5 (enExample) |